Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advances in the development of new tuberculosis drugs and treatment regimens

Nature Reviews Drug Discovery volume 12, pages 388–404 (2013)Cite this article

Subjects

Key Points

  • Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause significant morbidity and mortality worldwide.

  • After five decades of near inactivity in TB drug development, the past 5 years has seen the development of a promising TB drug pipeline. For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging.

  • Several new TB drug candidates are in Phase II and Phase III clinical trials in addition to high activity in the hit-to-lead and lead optimization stages.

  • New TB drug development has led to the submission of two new TB drugs for regulatory approval: delamanid (also known as OPC67683) and bedaquiline (also known as TMC207 or R207910).

  • The US Food and Drug Administration recently approved bedaquiline as part of a combination therapy in the treatment of adults with multidrug-resistant TB.

  • New TB treatment regimens aimed at reducing the duration of chemotherapy or for use against drug-resistant TB using new chemical entities are now progressing through clinical trials.

  • Many of the candidates in clinical trials are drugs that were developed to treat other infectious diseases and have since been repurposed for TB (for example, fluoroquinolones, rifamycins, oxazolidinones and clofazimine).

  • Several newer approaches are currently being pursued with the aim of reducing the time required for evaluating new TB drugs through the various phases of clinical trials. These include the use of 14-day early bactericidal activity (EBA) studies to rapidly determine bactericidal activity, the use of innovative trial designs that include multi-arm, multi-stage determinations of efficacy of new drug combinations, and the exploration and qualification of new surrogate markers of treatment effect.

  • To facilitate this more rapid evaluation of new TB drugs, current clinical trials are initially testing new combinations of TB drugs in patients with drug-susceptible pulmonary TB.

  • This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.

Abstract

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging. Such regimens are likely to utilize both repurposed drugs and new chemical entities, and several of these regimens are now progressing through clinical trials. This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Repurposed drugs for tuberculosis treatment.
Figure 2: Current global pipeline of new tuberculosis drugs.
Figure 3: Schematic showing the site of action of various tuberculosis drug candidates.
Figure 4: New clinical trials 'MAMS' design.

References

  1. Zumla, A., Raviglione, M., Hafner, R. & von Reyn, C. F. Tuberculosis. N. Engl. J. Med. 368, 745–755 (2013). An important update of current concepts on the clinical, epidemiological and management aspects of tuberculosis.

    Article  CAS  PubMed  Google Scholar 

  2. Grange, J. M. in Tuberculosis: A Comprehensive Clinical Reference (eds Schaaf, S. & Zumla, A. I.) 44–59 (Saunders, 2009).

    Book  Google Scholar 

  3. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677–686 (1999).

    Article  CAS  PubMed  Google Scholar 

  4. Diel, R. et al. Old ideas to innovate TB control: preventive treatment to achieve elimination. Eur. Respir. J. 8 Feb 2013 (10.1183/09031936.00205512).

  5. Raviglione, M. et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379, 1902–1913 (2012).

    Article  PubMed  Google Scholar 

  6. World Health Organization. Global Tuberculosis Report 2012 (WHO, 2012).

  7. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe (European Centre for Disease Prevention and Control, 2012).

  8. Hill, A. N., Becerra, J. & Castro, K. G. Modelling tuberculosis trends in the USA. Epidemiol. Infect. 140, 1862–1872 (2012).

    Article  CAS  PubMed  Google Scholar 

  9. Cohen, J. Infectious disease. Approval of novel TB drug celebrated — with restraint. Science 339, 130 (2013).

    Article  CAS  PubMed  Google Scholar 

  10. World Health Organization. Treatment of Tuberculosis Guidelines 4th edn (WHO, 2010).

  11. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC) 2nd edn (Tuberculosis Coalition for Technical Assistance, 2009)

  12. Johnson, J. L. et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am. J. Respir. Crit. Care Med. 180, 558–563 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lienhardt, C. et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study C randomized controlled trial. JAMA 305, 1415–1423 (2011).

    Article  CAS  PubMed  Google Scholar 

  14. Dooley, K. E. et al. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin. Infect. Dis. 55, 572–581 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Falzon, D. et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 38, 516–528 (2011).

    Article  CAS  PubMed  Google Scholar 

  16. Lawn, S. D. & Zumla, A. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect. Dis. 13, 349–361 (2013). A critical review of the Xpert MTB/RIF assay and the advantages and limitations of its utility in clinical practice.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Weyer, K. et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF. Eur. Respir. J. 22 Nov 2012 (10.1183/09031936.00157212).

  18. Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575–1580 (2006).

    Article  PubMed  Google Scholar 

  19. Dheda, K. et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 375, 1798–1807 (2010).

    Article  PubMed  Google Scholar 

  20. Jacobson, K. R., Tierney, D. B., Jeon, C. Y., Mitnick, C. D. & Murray, M. B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 51, 6–14 (2010).

    Article  PubMed  Google Scholar 

  21. Migliori, G. B. et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur. Respir. J. 11 Oct 2012 (10.1183/09031936.00136312).

  22. Udwadia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54, 579–581 (2012).

    Article  PubMed  Google Scholar 

  23. World Health Organization. “Totally Drug-Resistant TB”: a WHO consultation on the diagnostic definition and treatment options. World Health Organization[online], (2012).

  24. Cole, S. T. & Riccardi, G. New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 14, 570–576 (2011).

    Article  CAS  PubMed  Google Scholar 

  25. Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery for tuberculosis. Nature 469, 483–490 (2011).

    Article  CAS  PubMed  Google Scholar 

  26. Global-Alliance for TB Drug Development. Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb.) 81, (Suppl. 1), 1–52 (2001).

  27. Barry, C. E. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol. 7, 845–855 (2009).

    Article  CAS  Google Scholar 

  28. Jindani, A., Doré, C. J. & Mitchison, D. A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167, 1348–1354 (2003).

    Article  PubMed  Google Scholar 

  29. Donald, P. R. & Diacon, A. H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb.) 88, (Suppl. 1), 75–83 (2008).

    Article  Google Scholar 

  30. Nuermberger, E. L. et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169, 421–426 (2004).

    Article  PubMed  Google Scholar 

  31. Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J. & Wang, X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375, 2100–2109 (2010).

    Article  PubMed  Google Scholar 

  32. Rosenthal, I. M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4, e344 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Sterling, T. R. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 365, 2155–2166 (2011).

    Article  CAS  PubMed  Google Scholar 

  34. Diacon, A. H. et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51, 2994–2996 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. van Ingen, J. et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52, e194–e199 (2011).

    Article  CAS  PubMed  Google Scholar 

  36. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223–227 (2005). A landmark paper describing the discovery and development of bedaquiline and the validation of a novel yet ubiquitous new drug target for TB.

    Article  CAS  PubMed  Google Scholar 

  37. Dey, T. et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 68, 284–293 (2013).

    Article  CAS  PubMed  Google Scholar 

  38. Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182, 684–692 (2010). An observational “Bangladesh” standardized regimen study, with a duration of 9–12 months, that included gatifloxacin, ethambutol, pyrazinamide and clofazimine throughout, supplemented by kanamycin, prothionamide and isoniazid. During an intensive phase of 4 months this regimen achieved <1% failure and ∼90% relapse-free cure.

    Article  PubMed  Google Scholar 

  39. Verma, R. K. et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob. Agents Chemother. 57, 1050–1052 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zhang, M. et al. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56, 5782–5789 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Ashtekar, D. R. et al. Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 14, 465–471 (1991).

    Article  CAS  PubMed  Google Scholar 

  42. Fortun, J. et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56, 180–185 (2005).

    Article  CAS  PubMed  Google Scholar 

  43. Lee, M. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367, 1508–1518 (2012). A demonstration that linezolid, a drug with poor EBA, can improve the prognosis of patients with XDR-TB, thus providing hope that next-generation oxazolidinones may be even better.

    Article  CAS  PubMed  Google Scholar 

  44. Sotgiu, G. et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 40, 1430–1442 (2012).

    Article  CAS  PubMed  Google Scholar 

  45. Wallis, R. S. et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55, 567–574 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Wallis, R. S. et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202, 745–751 (2010).

    Article  CAS  PubMed  Google Scholar 

  47. Wallis, R. S. et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS ONE 7, e30479 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Reele, S. et al. A 14-day multiple ascending dose study: AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB) (Abstract A1-1735). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy [online], (2011).

    Google Scholar 

  49. Hugonnet, J. E. et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323, 1215–1218 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kumar, P. et al. Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol. 86, 367–381 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Dauby, N., Muylle, I., Mouchet, F., Sergysels, R. & Payen, M. C. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J. 30, 812–813 (2011).

    Article  PubMed  Google Scholar 

  52. De Lorenzo, S. et al. Efficacy and safety of meropenem/clavunate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur. Respir. J. 20 Sept 2012 (10.1183/09031936.00124312).

  53. Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol. 3, 323–324 (2007).

    Article  CAS  Google Scholar 

  54. Haagsma, A. C. et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 53, 1290–1292 (2009).

    Article  CAS  PubMed  Google Scholar 

  55. Huitric, E. et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 54, 1022–1028 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Biukovic, G. et al. Variations of subunit ε of the Mycobacterium tuberculosis F1F0 ATP synthase and a novel model for mechanism of action of the TB drug TMC207. Antimicrob. Agents Chemother. 57, 168–176 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273–25280 (2008).

    Article  CAS  PubMed  Google Scholar 

  58. Rao, S. P., Alonso, S., Rand, L., Dick, T. & Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 105, 11945–11950 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  59. Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397–2405 (2009). An important publication documenting the considerable impact of bedaquiline on the prognosis of patients with MDR-TB and the value of testing new drugs in MDR cohorts.

    Article  CAS  PubMed  Google Scholar 

  60. Veziris, N. et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 179, 75–79 (2009).

    Article  CAS  PubMed  Google Scholar 

  61. Lounis, N. et al. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J. Clin. Microbiol. 46, 2212–2215 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Lin, P. L. et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl Acad. Sci. USA 109, 14188–14193 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  63. Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962–966 (2000).

    Article  CAS  PubMed  Google Scholar 

  64. Matsumoto, M. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, e466 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Manjunatha, U. H. et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 431–436 (2006).

    Article  CAS  PubMed  Google Scholar 

  66. Singh, R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392–1395 (2008). An important publication documenting a novel M. tuberculosis killing mechanism mediated by PA-824 (and later by delaminid) that provides proof of concept for developing novel NO donor drugs for treating TB.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Manjunatha, U. H. et al. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob. Agents Chemother. 50, 3350–3354 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hurdle, J. G. et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemother. 62, 1037–1045 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Manjunatha, U., Boshoff, H. I. & Barry, C. E. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215–218 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Diacon, A. et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824; Antimicrob. Agents Chemother. 56, 3027–3031 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Diacon, A. H. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380, 986–993 (2012). A seminal study describing how the use of EBA with combination therapies has the potential to reduce the time needed for developing new multidrug regimens.

    Article  CAS  PubMed  Google Scholar 

  72. Diacon, A. H. et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 15, 949–954 (2011).

    Article  CAS  PubMed  Google Scholar 

  73. Gler, M. T. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 366, 2151–2160 (2012). An encouraging publication demonstrating that delamanid could enhance treatment options for patients with MDR-TB.

    Article  CAS  PubMed  Google Scholar 

  74. Skripconoka, V. et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur. Respir. J. 27 Sept 2012 (10.1183/09031936.00125812).

  75. Lee, R. E. et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5, 172–187 (2003).

    Article  CAS  PubMed  Google Scholar 

  76. Tahlan, K. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 1797–1809 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Reddy, V. M., Einck, L., Andries, K. & Nacy, C. A. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54, 2840–2846 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Grzegorzewicz, A. E. et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nature Chem. Biol. 8, 334–341 (2012).

    Article  CAS  Google Scholar 

  79. La Rosa, V. et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56, 324–331 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Stanley, S. A. et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7, 1377–1384 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801–804 (2009). A landmark paper presenting both a new chemical entity and a novel drug target for TB therapy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Pasca, M. R. et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother. 54, 1616–1618 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Lechartier, B., Hartkoorn, R. C. & Cole, S. T. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 5790–5793 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Neres, J. et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med. 4, 150ra121 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Trefzer, C. et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 132, 13663–13665 (2010).

    Article  CAS  PubMed  Google Scholar 

  86. Trefzer, C. et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase DprE1. J. Am. Chem. Soc. 134, 912–915 (2012).

    Article  CAS  PubMed  Google Scholar 

  87. Christophe, T. et al. High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5, e1000645 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Magnet, S. et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb.) 90, 354–360 (2010).

    Article  CAS  Google Scholar 

  89. Nunn, A. J., Phillips, P. P. & Mitchison, D. A. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int. J. Tuberc. Lung Dis. 14, 241–242 (2010).

    CAS  PubMed  Google Scholar 

  90. Merle, C. S. et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the gatifloxacin for TB (OFLOTUB) project. Trials 13, 61 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Phillips, P. P. et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J. Infect. Dis. 205, (Suppl. 2), 250–257 (2012).

    Article  Google Scholar 

  92. Wallis, R. et al. Tuberculosis biomarkers discovery: developments, needs and challenges. Lancet Infect. Dis. 13, 362–372 (2013). An important review of the latest information on progress on TB biomarkers development.

    Article  PubMed  Google Scholar 

  93. Horne, D. J. et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10, 387–394 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  94. Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J. & Zumla, A. Immunological biomarkers of tuberculosis. Nature Rev. Immunol. 11, 343–354 (2011).

    Article  CAS  Google Scholar 

  95. McNerney, R. et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J. Infect. Dis. 205 (Suppl. 2), 147–158 (2012).

    Article  Google Scholar 

  96. Nahid, P. et al. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am. J. Respir. Crit. Care Med. 184, 972–979 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  97. Skrahina, A. et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur. Respir. J. 39, 1425–1431 (2012).

    Article  PubMed  Google Scholar 

  98. Abubakar, I. et al. Drug resistant tuberculosis: time for visionary political leadership. Lancet Infect. Dis. 24 Mar 2013 (10.1016/S1473-3099(13)70030-6).

  99. Schatz, A., Bugie, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55, 66–69 (1944).

    Article  CAS  Google Scholar 

  100. Wassersug, J. D. Pulmonary tuberculosis. N. Engl. J. Med. 235, 220–229 (1946).

    Article  CAS  PubMed  Google Scholar 

  101. Marshall, G. Streptomycin in the treatment of pulmonary tuberculosis. A Medical Research Council investigation. BMJ 1, 382–386 (1949).

    Article  Google Scholar 

  102. American Thoracic Society. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603–662 (2003).

  103. Gengiah, T. N., Gray, A. L., Naidoo, K. & Karim, Q. A. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin. Drug Saf. 10, 559–574 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Havlir, D. V. et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 365, 1482–1491 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Blanc, F. X. et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365, 1471–1481 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. De Cock, K. M. & El-Sadr, W. M. When to start ART in Africa — an urgent research priority. N. Engl. J. Med. 368, 886–889 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Subbian, S. et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 7, e1002262 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Tobin, D. M. et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434–446 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Skerry, C., Harper, J., Klunk, M., Bishai, W. R. & Jain, S. K. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS ONE 7, e39680 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Napier, R. J. et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10, 475–485 (2012).

    Article  CAS  Google Scholar 

  111. Ivanyi, I. & Zumla, A. Non-steroidal anti-inflammatory drugs for adjunctive tuberculosis treatment. J. Infect. Dis. 5 Apr 2013 (10.1093/infdis/jit153).

  112. Amaral, L., Martins, M. & Viveiros, M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59, 1237–1246 (2007).

    Article  CAS  PubMed  Google Scholar 

  113. Adams, K. N. et al. Drug tolerance in replicating mycobacteria mediate macrophage-induced efflux mechanism. Cell 145, 39–53 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Lim, L. E. et al. Anthelmintic avermectins kill M. tuberculosis, including multidrug-resistant clinical strains. Antimicrob. Agents Chemother. 57, 1040–1046 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Maiga, M. et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE 7, e30749 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Uhlin, M., Andersson, J., Zumla, A. & Maeurer, M. Adjunct immunotherapies for tuberculosis. J. Infect. Dis. 205 (Suppl. 2), 325–334 (2012).

    Article  CAS  Google Scholar 

  117. Bruns, H. et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol. 189, 4069–4078 (2012).

    Article  CAS  PubMed  Google Scholar 

  118. Kuijl, C. et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature. 450, 725–730 (2007).

    Article  CAS  PubMed  Google Scholar 

  119. Boshoff, H. I. & Barry, C. E. 3rd. Tuberculosis — metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70–80 (2005).

    Article  CAS  Google Scholar 

  120. Pym, A. S. & Cole, S. T. in Bacterial Resistance to Antimicrobials 2nd Edn (eds Wax, R. G., Lewis, K., Salyers, A. A. & Taber, H.) 313–342 (CRC, 2008).

    Google Scholar 

  121. Shi, W. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333, 1630–1632 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Chakraborty, S., Gruber, T., Barry, C. E. 3rd, Boshoff, H. I. & Rhee, K. Y. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339, 88–91 (2013).

    Article  CAS  PubMed  Google Scholar 

  123. Sirgel, F. A. et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 67, 1088–1093 (2012).

    Article  CAS  PubMed  Google Scholar 

  124. Sirgel, F. A. et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb. Drug Resist. 18, 193–197 (2012).

    Article  CAS  PubMed  Google Scholar 

  125. Salian, S. et al. Structure–activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups. Antimicrob. Agents Chemother. 56, 6104–6108 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Global Alliance for TB Drug Development. Cycloserine. Tuberculosis (Edinb.) 88, 100–101 (2008).

  127. Bruning, J. B., Murillo, A. C., Chacon, O., Barletta, R. G. & Sacchettini, J. C. Structure of the Mycobacterium tuberculosis d-alanine:d-alanine ligase, a target of the antituberculosis drug d-cycloserine. Antimicrob. Agents Chemother. 55, 291–301 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Benator, D. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528–534 (2002).

    Article  PubMed  Google Scholar 

  129. Steingart, K. R., et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuber. Lung Dis. 15, 305–316 (2011).

    CAS  Google Scholar 

  130. Batt, S. M., et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl Acad. Sci. USA 109, 11354–11359 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The work of S.T.C. is supported by the European Community's Seventh Framework Programme (FP7/2007–2013) under the grant agreement number 260872. The work of A.Z. is supported by the Medical Research Council, UK, the European Union FP7, the European Developing Countries Clinical Trials Partnership, the National Institutes for Health Research (NIHR) University College London (UCL) Hospitals NHS Trust Biomedical Research Centre and the UBS Optimus Foundation, Switzerland. The work of P.N. is supported by the National Institutes of Health through National Institute of Allergy and Infectious Diseases funding (1R01AI104589), the Centers for Disease Control and Prevention TB Trials Consortium, and the Bill and Melinda Gates Foundation. Adam Zumla, UCL School of Pharmacy, UK, provided technical and administrative assistance.

Author information

Authors and Affiliations

  1. Division of Infection and Immunity, Center for Clinical Microbiology, University College London Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK

    Alimuddin Zumla

  2. Division of Pulmonary and Critical Care, University of California, San Francisco at San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, 94110, California, USA

    Payam Nahid

  3. Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, SV-GHI-UPCOL, Station 19, Lausanne, CH-1015, Switzerland

    Stewart T. Cole

Authors
  1. Alimuddin Zumla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Payam Nahid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stewart T. Cole
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stewart T. Cole.

Ethics declarations

Competing interests

Stewart T. Cole is named as the inventor on patents or patent applications related to the work in this article.

Related links

PowerPoint slides

Glossary

Multidrug-resistant TB

(MDR-TB). Tuberculosis (TB) caused by Mycobacterium tuberculosis bacilli that are resistant to at least isoniazid and rifampicin.

Extensively drug-resistant TB

(XDR-TB). Tuberculosis (TB) caused by Mycobacterium tuberculosis bacilli that are resistant to rifampicin, isoniazid, plus any fluoroquinolone and at least one of the three injectable second-line drugs: amikacin, kanamycin and capreomycin.

Directly observed therapy

(DOT). An approach to patient management that involves carers directly observing patients taking their tuberculosis drugs.

Drug-susceptible TB

Tuberculosis (TB) caused by Mycobacterium tuberculosis bacilli that is susceptible to first-line TB drugs.

Early bactericidal activity

(EBA). A commonly used assay in which the Mycobacterium tuberculosis bacilli load in sputum from the lungs of infected patients is periodically monitored for loss of viability, or culture conversion, using microbiological techniques. The duration of the assay has been extended from 7 days to 14 days since its conception.

Antiretroviral therapy

(ART). A combination of antiviral drugs used for treatment of diseases due to HIV.

Randomized, controlled clinical trial

The random allocation of patients to therapeutic regimens after enrolment. Assurances on strict adherence to interventions and minimizing losses from the trial population throughout treatment and follow-up are also key elements of randomized clinical trials.

Repurposed drugs

In this article, these are drugs that were developed to treat other diseases and have since been repurposed for treating tuberculosis.

Immune reconstitution inflammatory syndrome

Describes a collection of inflammatory disorders that are associated with the paradoxical worsening of pre-existing infectious conditions following the initiation of antiretroviral therapy in HIV-infected individuals.

Biomarker

A host or pathogen (for example, Mycobacterium tuberculosis) characteristic that is objectively measured and evaluated as an indicator of normal biological processes or pathogenic processes, or as an indicator of pharmacological responses to a therapeutic intervention.

Paucibacillary disease

Pulmonary tuberculosis with low Mycobacterium tuberculosis load in sputum.

Biobanks

Repositories that store biospecimens and data obtained from well-characterized patient cohorts who have had adequate follow-up for therapeutic failure and relapse. Biobanks will constitute a significant resource for the biomarker discovery field.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zumla, A., Nahid, P. & Cole, S. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12, 388–404 (2013). https://doi.org/10.1038/nrd4001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4001

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing